Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Sanghoon Lee; Li Zhao; Christine Rojas; Nicholas W. Bateman; Hui Yao; Olivia D. Lara; Joseph Celestino; Margaret B. Morgan; Tri V. Nguyen; Kelly A. Conrads; Kelly M. Rangel; Robert L. Dood; Richard A. Hajek; Gloria L. Fawcett; Randy A. Chu; Katlin Wilson; Jeremy L. Loffredo; Coralie Viollet; Amir A. Jazaeri; Clifton L. Dalgard; Xizeng Mao; Xingzhi Song; Ming Zhou; Brian L. Hood; Nirad Banskota; Matthew D. Wilkerson; Jerez Te; Anthony R. Soltis; Kristin Roman; Andrew Dunn; David Cordover; Agda Karina Eterovic; Jinsong Liu; Jared K. Burks; Keith A. Baggerly; Nicole D. Fleming; Karen H. Lu; Shannon N. Westin; Robert L. Coleman; Gordon B. Mills; Yovanni Casablanca; Jianhua Zhang; Thomas P. Conrads; George L. Maxwell; P. Andrew Futreal; Anil K. Sood

doi:10.1016/j.celrep.2020.03.066

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Sanghoon Lee, Li Zhao, Christine Rojas, Nicholas W. Bateman, Hui Yao, Olivia D. Lara, Joseph Celestino, Margaret B. Morgan, Tri V. Nguyen, Kelly A. Conrads, Kelly M. Rangel, Robert L. Dood, Richard A. Hajek, Gloria L. Fawcett, Randy A. Chu, Katlin Wilson, Jeremy L. Loffredo, Coralie Viollet, Amir A. Jazaeri, Clifton L. DalgardXizeng Mao, Xingzhi Song, Ming Zhou, Brian L. Hood, Nirad Banskota, Matthew D. Wilkerson, Jerez Te, Anthony R. Soltis, Kristin Roman, Andrew Dunn, David Cordover, Agda Karina Eterovic, Jinsong Liu, Jared K. Burks, Keith A. Baggerly, Nicole D. Fleming, Karen H. Lu, Shannon N. Westin, Robert L. Coleman, Gordon B. Mills, Yovanni Casablanca, Jianhua Zhang, Thomas P. Conrads, George L. Maxwell, P. Andrew Futreal, Anil K. Sood

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.

Original language	English (US)
Article number	107502
Journal	Cell Reports
Volume	31
Issue number	2
DOIs	https://doi.org/10.1016/j.celrep.2020.03.066
State	Published - Apr 14 2020

Keywords

R0 resection
copy number
genomics
immune monitoring
multi-omics
mutation
neoadjuvant chemotherapy
ovarian cancer
proteome
transcriptome

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

MD Anderson CCSG core facilities

Advanced Technology Genomics Core
Bioinformatics Shared Resource
Flow Cytometry and Cellular Imaging Facility
Functional Proteomics Reverse Phase Protein Array Core
Tissue Biospecimen and Pathology Resource
Biospecimen Extraction Facility
Clinical Trials Office

Access to Document

10.1016/j.celrep.2020.03.066

Cite this

Lee, S., Zhao, L., Rojas, C., Bateman, N. W., Yao, H., Lara, O. D., Celestino, J., Morgan, M. B., Nguyen, T. V., Conrads, K. A., Rangel, K. M., Dood, R. L., Hajek, R. A., Fawcett, G. L., Chu, R. A., Wilson, K., Loffredo, J. L., Viollet, C., Jazaeri, A. A., ... Sood, A. K. (2020). Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports, 31(2), Article 107502. https://doi.org/10.1016/j.celrep.2020.03.066

Lee, S , Zhao, L, Rojas, C, Bateman, NW, Yao, H, Lara, OD, Celestino, J, Morgan, MB, Nguyen, TV, Conrads, KA, Rangel, KM, Dood, RL, Hajek, RA, Fawcett, GL, Chu, RA, Wilson, K, Loffredo, JL, Viollet, C, Jazaeri, AA, Dalgard, CL, Mao, X , Song, X, Zhou, M, Hood, BL, Banskota, N, Wilkerson, MD, Te, J, Soltis, AR, Roman, K, Dunn, A, Cordover, D, Eterovic, AK, Liu, J , Burks, JK, Baggerly, KA, Fleming, ND , Lu, KH , Westin, SN, Coleman, RL, Mills, GB, Casablanca, Y, Zhang, J, Conrads, TP, Maxwell, GL, Futreal, PA & Sood, AK 2020, 'Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer', Cell Reports, vol. 31, no. 2, 107502. https://doi.org/10.1016/j.celrep.2020.03.066

@article{298aeb7ef1b64108b363d408a964b206,

title = "Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer",

abstract = "High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.",

keywords = "R0 resection, copy number, genomics, immune monitoring, multi-omics, mutation, neoadjuvant chemotherapy, ovarian cancer, proteome, transcriptome",

author = "Sanghoon Lee and Li Zhao and Christine Rojas and Bateman, {Nicholas W.} and Hui Yao and Lara, {Olivia D.} and Joseph Celestino and Morgan, {Margaret B.} and Nguyen, {Tri V.} and Conrads, {Kelly A.} and Rangel, {Kelly M.} and Dood, {Robert L.} and Hajek, {Richard A.} and Fawcett, {Gloria L.} and Chu, {Randy A.} and Katlin Wilson and Loffredo, {Jeremy L.} and Coralie Viollet and Jazaeri, {Amir A.} and Dalgard, {Clifton L.} and Xizeng Mao and Xingzhi Song and Ming Zhou and Hood, {Brian L.} and Nirad Banskota and Wilkerson, {Matthew D.} and Jerez Te and Soltis, {Anthony R.} and Kristin Roman and Andrew Dunn and David Cordover and Eterovic, {Agda Karina} and Jinsong Liu and Burks, {Jared K.} and Baggerly, {Keith A.} and Fleming, {Nicole D.} and Lu, {Karen H.} and Westin, {Shannon N.} and Coleman, {Robert L.} and Mills, {Gordon B.} and Yovanni Casablanca and Jianhua Zhang and Conrads, {Thomas P.} and Maxwell, {George L.} and Futreal, {P. Andrew} and Sood, {Anil K.}",

note = "Funding Information: A.A.J. consults with Roche/Genentech, Aravive, and Almac Group; has research funding from AstraZeneca, Pfizer, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics; honoraria from Gerson Lehrman Group; and travel support from AstraZeneca and MedImmune. K.R., A.D., and D.C. are employees of Akoya Biosciences. N.D.F. consults with Tesaro. S.N.W. has clinical research grants from AstraZeneca, ArQule, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, NCCN, Novartis, Roche/Genentech, and Tesaro and consults with AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, Takeda, and Tesaro. R.L.C. has clinical research grants from AstraZeneca, Merck, Clovis Oncology, Genmab, Roche/Genentech, Janssen, V Foundation, and Gateway for Cancer Research and consults with AstraZeneca, Merck, Tesaro, Medivation, Clovis Oncology, Genmab, GamaMabs, Agenus, Regeneron, OncoQuest, OncoSec, Roche/Genentech, and Janssen. G.B.M. consults with AstraZeneca, ImmunoMet, Ionis, Nuevolution, PDX Phamaceuticals, SignalChem, Symphogen, and Tarveda Therapeutics; has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Captial, and Tarveda Therapeutics; sponsored research from AstraZeneca, ImmunoMet, Pfizer, NanoString, and Tesaro and travel support from Chrysallis BioTherapeutics; and has licensed technology to NanoString and Myriad Genetics. Y.C.{\textquoteright}s spouse owns stock in Celsion. T.P.C. consults with Thermo Fisher Scientific and has research funding from AbbVie. G.L.M. consults with Merck, Kiyatek, Renovia, and Tesaro and has research funding from Merck. A.K.S. consults with Merck and Kiyatec, has research funding from M-Trap, and is a shareholder of Bio-Path Holdings. All other authors declare no competing interests. Funding Information: We thank S. Patterson (Department of Scientific Publications, MD Anderson Cancer Center, Houston, TX) for editorial assistance. We would like to acknowledge the MD Anderson Functional Proteomics Reverse Phase Protein Array Core for help with the RPPA assay, the MD Anderson Biospecimen Extraction Resource for extraction of genomic DNAs, the MD Anderson Research Histology Core Laboratory for IHC assay, and the Collaborative Health Initiative Research Program Laboratory Core for whole-genome sequencing library preparation and profiling. This work was supported in part by the MD Anderson Ovarian Cancer Moon Shot Program; National Institutes of Health (NIH) grants P50CA217685, R35CA209904, and P30CA016672 (used the Clinical Trials Office, Functional Proteomics Reverse Phase Protein Array Core, Research Histology Core Laboratory, and Cancer Genomics Laboratory); and the MD Anderson Center for Translational and Public Health Genomics (used the Biospecimen Extraction Resource). S.N.W. is supported by the Andrew Sabin Family Fellowship and the GOG Foundation Scholar Investigator Award. A.K.S. is supported by the American Cancer Society Research Professor Award and the Frank McGraw Memorial Chair in Cancer Research. O.D.L. is supported by an NIH institutional training grant (5T32CA009599). G.B.M. is supported by a kind gift from the Adelson Research Foundation; NIH grants U01CA217842, P50CA217685, P50CA098258,U24CA210950, and U54HG008100; Susan G. Komen grant SAC110052; Breast Cancer Research Foundation grant BCRF-17-108; the Ovarian Cancer Research Foundation; and Cancer Prevention and Research Institute of Texas grant RP170640. C.R. N.W.B. K.A.C. K.W. J.L.L. B.L.H. Y.C. T.P.C. and G.L.M. are supported by the Uniformed Services University of the Health Sciences award to the Gynecologic Cancer Center of Excellence (HU0001-16-2-0006), administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine. A.K.S. and P.A.F. supervised the study. S.L. Y.C. T.P.C. G.L.M. P.A.F. and A.K.S. conceived and designed the study. S.L. took the lead in writing the manuscript. S.L. L.Z. N.W.B. H.Y. O.D.L. T.P.C. and A.K.S. wrote the manuscript. S.L. L.Z. N.W.B. M.B.M. G.L.F. R.A.C. X.M. X.S. A.K.E. J.Z. T.P.C. P.A.F. and A.K.S. analyzed, managed, and interpreted the sequencing data. L.Z. C.V. C.L.D. N.B. M.D.W. J.T. A.R.S. J.Z. and P.A.F. analyzed and managed the WGS data. S.L. L.Z. J.Z. P.A.F. and A.K.S. interpreted the WGS data. S.L. L.Z. H.Y. J.Z. P.A.F. and A.K.S. analyzed and interpreted the RPPA data. S.L. and J.L. analyzed and interpreted the IHC data. K.R, A.D. and D.C performed the immune assessment. S.L. O.D.L. K.R. A.D. D.C. J.K.B. J.L. and A.K.S. analyzed and interpreted the immune assessment data. S.L. L.Z. C.R. N.W.B. K.A.C. K.W. J.L. M.Z. B.L.H. T.P.C. and A.K.S. analyzed and interpreted the LC-MS/MS data. S.L. J.C. T.V.N. K.M.R. R.L.D. A.A.J. J.L. K.A.B. N.D.F. K.H.L. S.N.W. R.L.C. G.B.M. and A.K.S. contributed to clinical samples and data acquisition. All authors read and approved the final manuscript. A.A.J. consults with Roche/Genentech, Aravive, and Almac Group; has research funding from AstraZeneca, Pfizer, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics; honoraria from Gerson Lehrman Group; and travel support from AstraZeneca and MedImmune. K.R. A.D. and D.C. are employees of Akoya Biosciences. N.D.F. consults with Tesaro. S.N.W. has clinical research grants from AstraZeneca, ArQule, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, NCCN, Novartis, Roche/Genentech, and Tesaro and consults with AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, Takeda, and Tesaro. R.L.C. has clinical research grants from AstraZeneca, Merck, Clovis Oncology, Genmab, Roche/Genentech, Janssen, V Foundation, and Gateway for Cancer Research and consults with AstraZeneca, Merck, Tesaro, Medivation, Clovis Oncology, Genmab, GamaMabs, Agenus, Regeneron, OncoQuest, OncoSec, Roche/Genentech, and Janssen. G.B.M. consults with AstraZeneca, ImmunoMet, Ionis, Nuevolution, PDX Phamaceuticals, SignalChem, Symphogen, and Tarveda Therapeutics; has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Captial, and Tarveda Therapeutics; sponsored research from AstraZeneca, ImmunoMet, Pfizer, NanoString, and Tesaro and travel support from Chrysallis BioTherapeutics; and has licensed technology to NanoString and Myriad Genetics. Y.C.?s spouse owns stock in Celsion. T.P.C. consults with Thermo Fisher Scientific and has research funding from AbbVie. G.L.M. consults with Merck, Kiyatek, Renovia, and Tesaro and has research funding from Merck. A.K.S. consults with Merck and Kiyatec, has research funding from M-Trap, and is a shareholder of Bio-Path Holdings. All other authors declare no competing interests. Funding Information: We thank S. Patterson (Department of Scientific Publications, MD Anderson Cancer Center, Houston, TX) for editorial assistance. We would like to acknowledge the MD Anderson Functional Proteomics Reverse Phase Protein Array Core for help with the RPPA assay, the MD Anderson Biospecimen Extraction Resource for extraction of genomic DNAs, the MD Anderson Research Histology Core Laboratory for IHC assay, and the Collaborative Health Initiative Research Program Laboratory Core for whole-genome sequencing library preparation and profiling. This work was supported in part by the MD Anderson Ovarian Cancer Moon Shot Program ; National Institutes of Health (NIH) grants P50CA217685 , R35CA209904 , and P30CA016672 (used the Clinical Trials Office, Functional Proteomics Reverse Phase Protein Array Core, Research Histology Core Laboratory, and Cancer Genomics Laboratory); and the MD Anderson Center for Translational and Public Health Genomics (used the Biospecimen Extraction Resource). S.N.W. is supported by the Andrew Sabin Family Fellowship and the GOG Foundation Scholar Investigator Award . A.K.S. is supported by the American Cancer Society Research Professor Award and the Frank McGraw Memorial Chair in Cancer Research . O.D.L. is supported by an NIH institutional training grant ( 5T32CA009599 ). G.B.M. is supported by a kind gift from the Adelson Research Foundation ; NIH grants U01CA217842 , P50CA217685 , P50CA098258 , U24CA210950 , and U54HG008100 ; Susan G. Komen grant SAC110052 ; Breast Cancer Research Foundation grant BCRF-17-108 ; the Ovarian Cancer Research Foundation ; and Cancer Prevention and Research Institute of Texas grant RP170640 . C.R., N.W.B., K.A.C., K.W., J.L.L., B.L.H., Y.C., T.P.C., and G.L.M. are supported by the Uniformed Services University of the Health Sciences award to the Gynecologic Cancer Center of Excellence ( HU0001-16-2-0006 ), administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine . Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = apr,

day = "14",

doi = "10.1016/j.celrep.2020.03.066",

language = "English (US)",

volume = "31",

journal = "Cell Reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

AU - Lee, Sanghoon

AU - Zhao, Li

AU - Rojas, Christine

AU - Bateman, Nicholas W.

AU - Yao, Hui

AU - Lara, Olivia D.

AU - Celestino, Joseph

AU - Morgan, Margaret B.

AU - Nguyen, Tri V.

AU - Conrads, Kelly A.

AU - Rangel, Kelly M.

AU - Dood, Robert L.

AU - Hajek, Richard A.

AU - Fawcett, Gloria L.

AU - Chu, Randy A.

AU - Wilson, Katlin

AU - Loffredo, Jeremy L.

AU - Viollet, Coralie

AU - Jazaeri, Amir A.

AU - Dalgard, Clifton L.

AU - Mao, Xizeng

AU - Song, Xingzhi

AU - Zhou, Ming

AU - Hood, Brian L.

AU - Banskota, Nirad

AU - Wilkerson, Matthew D.

AU - Te, Jerez

AU - Soltis, Anthony R.

AU - Roman, Kristin

AU - Dunn, Andrew

AU - Cordover, David

AU - Eterovic, Agda Karina

AU - Liu, Jinsong

AU - Burks, Jared K.

AU - Baggerly, Keith A.

AU - Fleming, Nicole D.

AU - Lu, Karen H.

AU - Westin, Shannon N.

AU - Coleman, Robert L.

AU - Mills, Gordon B.

AU - Casablanca, Yovanni

AU - Zhang, Jianhua

AU - Conrads, Thomas P.

AU - Maxwell, George L.

AU - Futreal, P. Andrew

AU - Sood, Anil K.

N1 - Funding Information: A.A.J. consults with Roche/Genentech, Aravive, and Almac Group; has research funding from AstraZeneca, Pfizer, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics; honoraria from Gerson Lehrman Group; and travel support from AstraZeneca and MedImmune. K.R., A.D., and D.C. are employees of Akoya Biosciences. N.D.F. consults with Tesaro. S.N.W. has clinical research grants from AstraZeneca, ArQule, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, NCCN, Novartis, Roche/Genentech, and Tesaro and consults with AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, Takeda, and Tesaro. R.L.C. has clinical research grants from AstraZeneca, Merck, Clovis Oncology, Genmab, Roche/Genentech, Janssen, V Foundation, and Gateway for Cancer Research and consults with AstraZeneca, Merck, Tesaro, Medivation, Clovis Oncology, Genmab, GamaMabs, Agenus, Regeneron, OncoQuest, OncoSec, Roche/Genentech, and Janssen. G.B.M. consults with AstraZeneca, ImmunoMet, Ionis, Nuevolution, PDX Phamaceuticals, SignalChem, Symphogen, and Tarveda Therapeutics; has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Captial, and Tarveda Therapeutics; sponsored research from AstraZeneca, ImmunoMet, Pfizer, NanoString, and Tesaro and travel support from Chrysallis BioTherapeutics; and has licensed technology to NanoString and Myriad Genetics. Y.C.’s spouse owns stock in Celsion. T.P.C. consults with Thermo Fisher Scientific and has research funding from AbbVie. G.L.M. consults with Merck, Kiyatek, Renovia, and Tesaro and has research funding from Merck. A.K.S. consults with Merck and Kiyatec, has research funding from M-Trap, and is a shareholder of Bio-Path Holdings. All other authors declare no competing interests. Funding Information: We thank S. Patterson (Department of Scientific Publications, MD Anderson Cancer Center, Houston, TX) for editorial assistance. We would like to acknowledge the MD Anderson Functional Proteomics Reverse Phase Protein Array Core for help with the RPPA assay, the MD Anderson Biospecimen Extraction Resource for extraction of genomic DNAs, the MD Anderson Research Histology Core Laboratory for IHC assay, and the Collaborative Health Initiative Research Program Laboratory Core for whole-genome sequencing library preparation and profiling. This work was supported in part by the MD Anderson Ovarian Cancer Moon Shot Program; National Institutes of Health (NIH) grants P50CA217685, R35CA209904, and P30CA016672 (used the Clinical Trials Office, Functional Proteomics Reverse Phase Protein Array Core, Research Histology Core Laboratory, and Cancer Genomics Laboratory); and the MD Anderson Center for Translational and Public Health Genomics (used the Biospecimen Extraction Resource). S.N.W. is supported by the Andrew Sabin Family Fellowship and the GOG Foundation Scholar Investigator Award. A.K.S. is supported by the American Cancer Society Research Professor Award and the Frank McGraw Memorial Chair in Cancer Research. O.D.L. is supported by an NIH institutional training grant (5T32CA009599). G.B.M. is supported by a kind gift from the Adelson Research Foundation; NIH grants U01CA217842, P50CA217685, P50CA098258,U24CA210950, and U54HG008100; Susan G. Komen grant SAC110052; Breast Cancer Research Foundation grant BCRF-17-108; the Ovarian Cancer Research Foundation; and Cancer Prevention and Research Institute of Texas grant RP170640. C.R. N.W.B. K.A.C. K.W. J.L.L. B.L.H. Y.C. T.P.C. and G.L.M. are supported by the Uniformed Services University of the Health Sciences award to the Gynecologic Cancer Center of Excellence (HU0001-16-2-0006), administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine. A.K.S. and P.A.F. supervised the study. S.L. Y.C. T.P.C. G.L.M. P.A.F. and A.K.S. conceived and designed the study. S.L. took the lead in writing the manuscript. S.L. L.Z. N.W.B. H.Y. O.D.L. T.P.C. and A.K.S. wrote the manuscript. S.L. L.Z. N.W.B. M.B.M. G.L.F. R.A.C. X.M. X.S. A.K.E. J.Z. T.P.C. P.A.F. and A.K.S. analyzed, managed, and interpreted the sequencing data. L.Z. C.V. C.L.D. N.B. M.D.W. J.T. A.R.S. J.Z. and P.A.F. analyzed and managed the WGS data. S.L. L.Z. J.Z. P.A.F. and A.K.S. interpreted the WGS data. S.L. L.Z. H.Y. J.Z. P.A.F. and A.K.S. analyzed and interpreted the RPPA data. S.L. and J.L. analyzed and interpreted the IHC data. K.R, A.D. and D.C performed the immune assessment. S.L. O.D.L. K.R. A.D. D.C. J.K.B. J.L. and A.K.S. analyzed and interpreted the immune assessment data. S.L. L.Z. C.R. N.W.B. K.A.C. K.W. J.L. M.Z. B.L.H. T.P.C. and A.K.S. analyzed and interpreted the LC-MS/MS data. S.L. J.C. T.V.N. K.M.R. R.L.D. A.A.J. J.L. K.A.B. N.D.F. K.H.L. S.N.W. R.L.C. G.B.M. and A.K.S. contributed to clinical samples and data acquisition. All authors read and approved the final manuscript. A.A.J. consults with Roche/Genentech, Aravive, and Almac Group; has research funding from AstraZeneca, Pfizer, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics; honoraria from Gerson Lehrman Group; and travel support from AstraZeneca and MedImmune. K.R. A.D. and D.C. are employees of Akoya Biosciences. N.D.F. consults with Tesaro. S.N.W. has clinical research grants from AstraZeneca, ArQule, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, NCCN, Novartis, Roche/Genentech, and Tesaro and consults with AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, Takeda, and Tesaro. R.L.C. has clinical research grants from AstraZeneca, Merck, Clovis Oncology, Genmab, Roche/Genentech, Janssen, V Foundation, and Gateway for Cancer Research and consults with AstraZeneca, Merck, Tesaro, Medivation, Clovis Oncology, Genmab, GamaMabs, Agenus, Regeneron, OncoQuest, OncoSec, Roche/Genentech, and Janssen. G.B.M. consults with AstraZeneca, ImmunoMet, Ionis, Nuevolution, PDX Phamaceuticals, SignalChem, Symphogen, and Tarveda Therapeutics; has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Captial, and Tarveda Therapeutics; sponsored research from AstraZeneca, ImmunoMet, Pfizer, NanoString, and Tesaro and travel support from Chrysallis BioTherapeutics; and has licensed technology to NanoString and Myriad Genetics. Y.C.?s spouse owns stock in Celsion. T.P.C. consults with Thermo Fisher Scientific and has research funding from AbbVie. G.L.M. consults with Merck, Kiyatek, Renovia, and Tesaro and has research funding from Merck. A.K.S. consults with Merck and Kiyatec, has research funding from M-Trap, and is a shareholder of Bio-Path Holdings. All other authors declare no competing interests. Funding Information: We thank S. Patterson (Department of Scientific Publications, MD Anderson Cancer Center, Houston, TX) for editorial assistance. We would like to acknowledge the MD Anderson Functional Proteomics Reverse Phase Protein Array Core for help with the RPPA assay, the MD Anderson Biospecimen Extraction Resource for extraction of genomic DNAs, the MD Anderson Research Histology Core Laboratory for IHC assay, and the Collaborative Health Initiative Research Program Laboratory Core for whole-genome sequencing library preparation and profiling. This work was supported in part by the MD Anderson Ovarian Cancer Moon Shot Program ; National Institutes of Health (NIH) grants P50CA217685 , R35CA209904 , and P30CA016672 (used the Clinical Trials Office, Functional Proteomics Reverse Phase Protein Array Core, Research Histology Core Laboratory, and Cancer Genomics Laboratory); and the MD Anderson Center for Translational and Public Health Genomics (used the Biospecimen Extraction Resource). S.N.W. is supported by the Andrew Sabin Family Fellowship and the GOG Foundation Scholar Investigator Award . A.K.S. is supported by the American Cancer Society Research Professor Award and the Frank McGraw Memorial Chair in Cancer Research . O.D.L. is supported by an NIH institutional training grant ( 5T32CA009599 ). G.B.M. is supported by a kind gift from the Adelson Research Foundation ; NIH grants U01CA217842 , P50CA217685 , P50CA098258 , U24CA210950 , and U54HG008100 ; Susan G. Komen grant SAC110052 ; Breast Cancer Research Foundation grant BCRF-17-108 ; the Ovarian Cancer Research Foundation ; and Cancer Prevention and Research Institute of Texas grant RP170640 . C.R., N.W.B., K.A.C., K.W., J.L.L., B.L.H., Y.C., T.P.C., and G.L.M. are supported by the Uniformed Services University of the Health Sciences award to the Gynecologic Cancer Center of Excellence ( HU0001-16-2-0006 ), administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine . Publisher Copyright: © 2020 The Author(s)

PY - 2020/4/14

Y1 - 2020/4/14

N2 - High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.

AB - High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.

KW - R0 resection

KW - copy number

KW - genomics

KW - immune monitoring

KW - multi-omics

KW - mutation

KW - neoadjuvant chemotherapy

KW - ovarian cancer

KW - proteome

KW - transcriptome

UR - http://www.scopus.com/inward/record.url?scp=85083004505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083004505&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2020.03.066

DO - 10.1016/j.celrep.2020.03.066

M3 - Article

C2 - 32294438

AN - SCOPUS:85083004505

SN - 2211-1247

VL - 31

JO - Cell Reports

JF - Cell Reports

IS - 2

M1 - 107502

ER -

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this